Polar Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | $14.6M | Buy |
100,000
+25,000
| +33% | +$3.64M | 0.11% | 161 |
|
|
2020
Q2 | $11.1M | Sell |
75,000
-75,000
| -50% | -$11.1M | 0.1% | 165 |
|
|
2020
Q1 | $16.3M | Buy |
150,000
+35,000
| +30% | +$3.81M | 0.18% | 141 |
|
|
2019
Q4 | $13.2M | Buy |
115,000
+5,000
| +5% | +$576K | 0.12% | 181 |
|
|
2019
Q3 | $8.85M | Sell |
110,000
-89,372
| -45% | -$7.19M | 0.08% | 206 |
|
|
2019
Q2 | $14.5M | Sell |
199,372
-5,645
| -3% | -$410K | 0.13% | 166 |
|
|
2019
Q1 | $19.2M | Sell |
205,017
-89,270
| -30% | -$8.34M | 0.18% | 154 |
|
|
2018
Q4 | $21.5M | Buy |
294,287
+50,000
| +20% | +$3.65M | 0.23% | 130 |
|
|
2018
Q3 | $21.4M | Buy |
244,287
+29,287
| +14% | +$2.56M | 0.18% | 148 |
|
|
2018
Q2 | $21.2K | Sell |
215,000
-226,232
| -51% | -$22.3K | 0.13% | 150 |
|
|
2018
Q1 | $52.6M | Sell |
441,232
-75,000
| -15% | -$8.93M | 0.53% | 60 |
|
|
2017
Q4 | $65.6M | Buy |
+516,232
| New | +$65.6M | 0.68% | 29 |
|
|
2015
Q2 | – | Sell |
-6,857
| Closed | -$716K | – | 286 |
|
|
2015
Q1 | $716K | Buy |
6,857
+487
| +8% | +$50.9K | 0.01% | 257 |
|
|
2014
Q4 | $618K | Sell |
6,370
-4,586
| -42% | -$445K | 0.01% | 255 |
|
|
2014
Q3 | $856K | Buy |
10,956
+6,198
| +130% | +$484K | 0.02% | 237 |
|
|
2014
Q2 | $301K | Buy |
+4,758
| New | +$301K | 0.01% | 259 |
|
|
2013
Q3 | – | Sell |
-419,830
| Closed | -$13M | – | 257 |
|
|
2013
Q2 | $13M | Buy |
+419,830
| New | +$13M | 0.45% | 78 |
|